SLN — Silence Therapeutics plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1479615 · United Kingdom
Last close
$19.80
Market Cap
$1.23B
52W High
$19.86
52W Low
$4.19
ADV30
4,197,261
Next earnings
2026-11-12
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 0 -14,224,000 -12,426,000 281,498,000 247,659,000 66,477,000
Jun 2026 0 0 -13,865,000 -12,268,000 106,412,000 72,054,000 67,941,000
Mar 2026 422,000 411,000 -15,737,000 -14,957,000 115,123,000 5,657,000 65,721,000
Dec 2025 34,000 22,000 -12,461,000 -11,770,000 131,442,000 11,277,000 69,138,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-42,263,000
Investing CF
$72,891,000
Financing CF
$2,000
CapEx
$-55,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.62
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-589,632,000
Inventory
—
Receivables
$9,292,000
ST Investments
$0
EBIT TTM
$-68,307,000
Pretax Income TTM
$-59,951,000
Interest Exp TTM
—
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$615,000
EBITDA
$-63,942,000
Free Cash Flow
$-23,567,624
Enterprise Value
$864,959,616
Total Cash
$72,054,000
Total Debt
$112,000
Shares Out
62,203,024
Trailing EPS
$-1.29
Book Value
$1.32
ROE
-90.4%
ROA
-29.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 559,000 -89,753,000 -88,612,000 131,442,000 69,138,000 62,304,000 -62,271,000
Dec 2024 43,258,000 -63,319,000 -45,309,000 202,635,000 68,612,000 134,023,000 -67,640,000
Dec 2023 31,643,000 -64,383,000 -54,228,000 119,448,000 97,455,000 21,993,000 -49,462,000
Dec 2022 21,655,000 -61,040,000 -50,334,000 130,096,453 103,384,928 26,711,525 -57,044,000

TTM Snapshot

Revenues TTM
$615,000
NetIncome TTM
$-59,953,000
OpCashFlow TTM
—
Assets (Latest)
$106,412,000
Forward EPS
$-0.38

Max Pain — expiry 2027-01-15

max pain strike: $17.50 · spot: $19.82 · call oi: 21,142 · put oi: 8,957
Expected Move to 2027-01-15: ±$0.36 (1.82%) — implied range $19.46 – $20.18 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KARD Kardigan, Inc. $1.23B $13.19 —
AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL $1.23B $13.14 —
NKTR NEKTAR THERAPEUTICS $1.23B $35.91 —
AMPH Amphastar Pharmaceuticals, Inc. $1.24B $29.10 —
AVLN Avalyn Pharma Inc. $1.24B $27.92 —

News headlines (Yahoo Finance, 1h cache)

Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
2026-11-12 13:00 · Yahoo
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
2026-11-04 14:00 · Yahoo
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
2026-10-20 12:59 · Yahoo
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
2026-10-20 12:55 · Yahoo
Is Silence Therapeutics (NasdaqGM:SLN) Reasonable Near Its $20 Deal Price?
2026-10-20 01:09 · Yahoo
Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%
2026-10-19 23:41 · Yahoo
Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
2026-10-19 16:08 · Yahoo
Silence Therapeutics jumps 59% on Merck takeover
2026-10-19 15:20 · Yahoo
Silence Therapeutics stock soars 125% on Merck acquisition
2026-10-19 13:56 · Yahoo
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
2026-10-19 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.